By Dean Seal
Eli Lilly has unleashed another wave of litigation against four telehealth brands in its widening legal war with sellers of alternative versions of its popular diabetes and weight-loss drugs.
The large drugmaker on Wednesday filed four lawsuits targeting Mochi Health, Fella & Delilah Health, Willow Health and Henry Meds over their sales of knockoff versions of tirzepatide, the active ingredient in its diabetes drug Mounjaro and obesity drug Zepbound.
Each of the telehealth companies are alleged by Lilly to have misled consumers and patients in their marketing of the compounded tirzepatide products and driven them away from safer medicines.
Representatives for the four companies didn't immediately respond to requests for comment.
The actions filed in California federal courts are Lilly's latest attempt to crack down on the sale of custom-made versions of its drugs, which have faced shortages due to high demand, leading to a surge of cheaper, alternative versions.
Lilly has filed lawsuits against med-spas, wellness centers and other entities for selling products that purportedly containing tirzepatide, claiming in some cases that the defendants falsely label their products as Mounjaro and Zepbound, as being the same as those drugs, as being part of Eli Lilly's clinical trials, or as being approved by federal regulators.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 23, 2025 10:54 ET (14:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。